Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study [Breast Cancer]

Conclusion
The addition of bevacizumab to ET in first-line treatment failed to produce a statistically significant increase in PFS or OS in women with HER2-negative/hormone receptor–positive advanced breast cancer.

Source: Journal of Clinical Oncology - March 18, 2015 Category: Cancer & Oncology Authors: Martin, Loibl, von Minckwitz, Morales, Martinez, Guerrero, Anton, Aktas, Schoenegg, Munoz, Garcia-Saenz, Gil, Ramos, Margeli, Carrasco, Liedtke, Wachsmann, Mehta, De la Haba-Rodriguez Tags: Hormonal Therapy Breast Cancer Source Type: research